SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Smirnova IO. Experimental bases of treatment of mastopathy with iodine microdoses. PhD Thesis. Moscow: All-Union Cancer Center, 1966.
  • 2
    Anisimov VN. The light-dark regimen and cancer development. Neuroendocrinol Lett 2002; 23 (Suppl): 2836.
  • 3
    Blask DE, Dauchy RT, Sauer LA, Krause JA, Brainard HC. Light during darkness, melatonin suppression and cancer progression. Neuroendocrinol Lett 2002; 23 (Suppl): 526.
  • 4
    Brainard GC, Kaver R, Kheifets LI. The relationship between electromagnetic field and light exposure to melatonin and breast cancer risk: a review of the relevant literature. J Pineal Res 1999; 26: 65100.
  • 5
    Khaetski IK. Effect of hypothalamo-pituitary lesions induced by constant illumination on development of induced mammary tumors in rats. Vopr Exp Oncol (Kiev) 1965; 1: 8793.
  • 6
    Anisimov VN, Zhukova OV, Beniashvili DSh, Bilanishivili VG, Menabde MZ. Light deprivation, electromagnetic fields and mammary carcinogenesis. Adv Pineal Res 1994; 7: 22934.
  • 7
    Arendt J. Melatonin and the mammalian pineal gland. London: Chapman and Hall, 1995.
  • 8
    Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991; 12: 15180.
  • 9
    Hansen J. Increased breast cancer risk among women who work predominantly at night. Ann Epidemiol 2001; 12: 747.
  • 10
    Davis S, Mirck DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 2001; 93: 155762.
  • 11
    Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Colditz GA. Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst 2001; 93: 15638.
  • 12
    Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Fuchs CS, Colditz GA. Night-shifts work and risk of colorectal cancer in the nurses' health study. J Natl Cancer Inst 2003; 5: 8258.
  • 13
    Stevens RG, Rea MS. Light in the built environment: potential role of circadian disruption in endocrine disruption and breast cancer. Cancer Causes Control 2001; 12: 27987.
  • 14
    Deerberg F, Bartsch C, Pohlmeyer G, Bartsch H. Effect of melatonin and physiological epiphysectomy on the development of spontaneous endometrial carcinoma in BDII/Han rats. Cancer Biother Radiother 1997; 12: 420.
  • 15
    Heiligenberg van den S, Depres-Brummer P, Barbason H, Claustrat B, Reynes M, Levi F, The tumor promoting effect of constant light exposure on diethylnitrosamine-induced hepatocarcinogenesis in rats. Life Sci 1999; 64: 252334.
  • 16
    Beniashvili DS, Benjamin S, Baturin DA, Anisimov VN. Effect of light/dark regimen on N-nitrosomethylurea-induced transplacental carcinogenesis in rats. Cancer Lett 2001; 163: 517.
  • 17
    Goto M, Oshima I, Tomita T, Ebihara S. Melatonin content of the pineal gland in different mouse strains. J Pineal Res 1989; 7: 195204.
  • 18
    Anisimov VN, Alimova IN, Baturin DA, Popovich IG, Zabezhinski MA, Manton KG, Semenchenko AV, Yashin AI. The effect of melatonin treatment regimen on mammary adenocarcinoma development in HER-2/neu transgenic mice. Int J Cancer 2003; 103: 3005.
  • 19
    Anisimov VN, Ailamazyan EK, Baturin DA, Zabezhinski MA, Alimova IN, Popovich IG, Beniashvili DS, Manton KG, Proviciali M, Franceschi C. Light regimen, anovulation, and risk of malignant tumors of the female reproductive system: the mechanisms of link and prevention. J Obstet Woman Dis 2003; 52: 4758.
  • 20
    Turusov VS, Mohr U, eds. Pathology of tumours in laboratory animals. vol. 1. Tumours of the mouse. 2nd ed. (IARC Sci. Publ. No 111). Lyon: IARC, 1994.
  • 21
    Goubler EV. Computing methods of pathology analysis and recognition. Leningrad: Meditsina, 1978.
  • 22
    Gart JJ, Krewski D, Lee PN, Tarone S, Wahrendorf J. Statistical methods in cancer research. Vol. IIIThe design and analysis of long-term animal experiments. IARC Scientific Publication 79. IARC, Lyon: IARC, 1986.
  • 23
    Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall, 1996.
  • 24
    Taron RE. Tests for trend in life table analysis. Biometrika 1975; 62: 67982.
  • 25
    Gauss System and Graphic Manual. Maple Valley: Aptech Systems, Inc., 1994.
  • 26
    Anisimov VN. Carcinogenesis and aging. Vol 2. Boca Raton: CRC Press, 1987.
  • 27
    Mahajan DK. Polycystic ovarian disease: animal models. Endocrinol Metab Clin North Am 1988; 17: 70532.
  • 28
    Dilman VM, Anisimov VN. 1979. Hypothalamic mechanisms of ageing and of specific age pathology - I. Sensitivity threshold of hypothalamo-pituitary complex to homeostatic stimuli in the reproductive system. Exp Gerontol 1979; 14: 16174.
  • 29
    Anisimov V.N. Molecular and physiological mechanisms of aging. St. Petersburg: Nauka, 2003.
  • 30
    Rossmanith WG. Gonadotropin secretion during aging in women: review article. Exp Gerontol 1996; 30: 36981.
  • 31
    Jochle W. Trends in photophysiologic concepts. Ann NY Acad Sci 1964; 117: 88104.
  • 32
    Baturin DA, Alimova IN, Anisimov VN, Popovich IG, Zabezhinski MA, Provinciali M, Mancini R, Franceschi C. Effect of light regimen and melatonin on the development of spontaneous mammary tumors in HER-2/neu transgenic mice is related to a downregulation of HER-2/neu gene expression. Neuroendocrinol Lett 2001; 22: 43945.
  • 33
    Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem 2002; 2: 11332.
  • 34
    Hermann R, Podhajsky S, Jungnickel S, Lerchl A. Potentiation of antiproliferative effects of tamoxifen and ethanol on mouse hepatoma cells by melatonin: possible involvement of mitogen-activated protein kinase and induction of apoptosis. J Pineal Res 2002; 33: 813.
  • 35
    Cini G, Coronnello M, Mini E, Neri B. Melatonin's growth-inhibitory effect on hepatoma AH 130 in the rat. Cancer Lett 1998; 125: 519.
  • 36
    Imaida K, Hagiwara A, Yoshino H, Tamano S, Sano M, Futakuchi M, Ogawa K, Asamoto M, Shirai T. Inhibitory effect of low doses of melatonin on induction of preneoplastic liver lesions in a medium-term liver bioassay in F344 rats: relation to the influence of electromagnetic near field exposure. Cancer Lett 2000; 155: 10514.
  • 37
    Andant C, Puy H, Bogard C, Faivre J, Soule JC, Nordmann Y, Deybacj JC. Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol 2000; 32: 9339.
  • 38
    Tillmann T, Kamino K, Mohr U. Incidence and spectrum of spontaneous neoplasms in male and female CBA/J mice. Exp Toxicol Pathol 2000; 52: 2215.
  • 39
    Anisimov VN, Zavarzina NY, Zabezhinski MA, Popovich IG, Zimina OA, Shtylick AV, Michalski AI, Yashin AI. Melatonin increases both life span and tumor incidence in female CBA mice. J Gerontol Biol Sci 2001; 56A: B31123.
  • 40
    Bell JA, Sneddon A, Hamilton T. Influence of light and 9,10-dimethylbenz(a) anthracene on rat ovarian steroidogenesis: neutral steroids. Biochem J 1968; 110: 29p30p.
  • 41
    Smyth BJ, Sneddon A, Hamilton T. Influence of light and 9,10-dimethylbenz(a)-anthracene on rat ovarian steroidogenesis: phenolic steroids. Biochem J 1968; 110: 28p9p.
  • 42
    Sanchez-Barcelo EJ, Cos S, Fernandez R, Mediavilla MD. Melatonin and mammary cancer: a short review. Endocr Relat Cancer 2003; 10: 1539.
  • 43
    Anisimov VN, Zabezhinski MA, Popovich IG, Zaripova EA, Musatov SA, Andre V, Vigreux C, Godard T, Sichel F. Inhibitory effect of melatonin on 7,12-dimethylbenz [a]anthracene-induced carcinogenesis of the uterine cervix and vagina in mice and mutagenesis in vitro. Cancer Lett 2000; 156: 199205.
  • 44
    Anisimov VN, Popovich IG, Zabezhinski MA. Melatonin and colon carcinogenesis: Inhibitory effects of melatonin on development of intestinal tumors induced by 1,2-dimethylhydrazine in rats. Carcinogenesis 1997; 18: 154953.
  • 45
    Anisimov VN. Melatonin and colon carcinogenesis. In: BartschC, BartschH, BlaskDE, CardinaliDP, HrusheskyWJM, MeckeD, eds. The pineal gland and cancer. Neuroimmunoendocrine mechanisms in malignancy. Berlin: Springer, 2001. 24058.
  • 46
    Blask DE. An overview on the neuroendocrine regulation of experimental tumor growth by melatonin and its analogues and the therapeutic use of melatonin in oncology. In: BartschC, BartschH, BlaskDE, CardinaliDP, HrusheskyWJM, MeckeD, eds. The pineal gland and cancer. Neuroimmunoendocrine mechanisms in malignancy. Berlin: Springer, 2001. 30942.
  • 47
    Reiter RJ. Reactive oxygen species, DNA damage, and carcinogenesis: intervention with melatonin. In: BartschC, BartschH, BlaskDE, CardinaliDP, HrusheskyWJM, MeckeD, eds. The pineal gland and cancer. Neuroimmunoendocrine mechanisms in malignancy. Berlin: Springer, 2001. 44255.
  • 48
    Sainz RM, Mayo JC, Rodriguez C, Tan DX, Lopez-Burillo S, Reiter RJ. Melatonin and cell death: differential actions on an apoptosis in normal and cancer cells. Cell Mol Life Sci 2003; 60: 140726.
  • 49
    Leon-Blanco MM, Guerrero JM, Reiter RJ, Calvo JR, Pozo D. Melatonin inhibits telomerase activity in theMCF-7 tumor cell line both in vivo and in vitro. J Pineal Res 2003; 35: 20411.